Literature DB >> 26280510

Whole-Genome Sequencing of Growth Hormone (GH)-Secreting Pituitary Adenomas.

Niko Välimäki1, Hande Demir1, Esa Pitkänen1, Eevi Kaasinen1, Atte Karppinen1, Leena Kivipelto1, Camilla Schalin-Jäntti1, Lauri A Aaltonen1, Auli Karhu1.   

Abstract

CONTEXT: The somatic landscape of pituitary adenomas is largely unknown. Identification of somatic alterations aims at better understanding of tumor pathology.
OBJECTIVE: The objective of the study was a genome-wide characterization of somatic single-nucleotide variants, structural variants, and copy-number aberrations in somatotropinomas. DESIGN AND
SETTING: Whole-genome sequencing and single-nucleotide polymorphism array analyses were performed on 12 fresh-frozen somatotropinomas and their corresponding blood samples. All the coding somatic variants were confirmed by Sanger sequencing. PATIENTS: Studied tumors were somatotropinomas. Apart from one AIP mutation-positive patient, all cases were mutation negative for the established germline mutations associated with pituitary adenomas. INTERVENTION(S): There were no interventions. MAIN OUTCOME MEASURES: Somatic variants were identified with an established computational pipeline and filtered against germline data. Somatic copy number alteration analyses were performed using segmentation-based approaches.
RESULTS: A genome-wide analysis revealed on average 129 somatic single-nucleotide variants per tumor. Further analysis of coding regions showed on average 2.3 single-nucleotide variants per tumor. The only recurrent somatic events were the oncogenic GNAS mutation (p.Arg201Cys) and shared chromosome losses (chromosomes 1, 6, 13, 14, 15, 16, 18, 22). Analysis of somatic structural variants revealed one tumor with a complex chromosomal rearrangement.
CONCLUSIONS: Somatotropinomas showed a low number of somatic genetic alterations. Whereas no novel recurrently mutated genes could be identified, the somatic landscape has potential to affect the Ca(2+) and ATP pathways known to be involved in the pituitary tumorigenesis. Further studies, eg, methylome and transcriptome analyses, are needed to investigate possible interplay between the recurrent chromosome losses and epigenetic factors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26280510     DOI: 10.1210/jc.2015-3129

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

Review 1.  Pituitary Medicine From Discovery to Patient-Focused Outcomes.

Authors:  Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

2.  Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors.

Authors:  Wenya Linda Bi; Noah F Greenwald; Shakti H Ramkissoon; Malak Abedalthagafi; Shannon M Coy; Keith L Ligon; Yu Mei; Laura MacConaill; Matt Ducar; Le Min; Sandro Santagata; Ursula B Kaiser; Rameen Beroukhim; Edward R Laws; Ian F Dunn
Journal:  Endocrinology       Date:  2017-07-01       Impact factor: 4.736

Review 3.  The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.

Authors:  Daniela Regazzo; Mattia Barbot; Carla Scaroni; Nora Albiger; Gianluca Occhi
Journal:  Rev Endocr Metab Disord       Date:  2020-03       Impact factor: 6.514

4.  Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.

Authors:  Hiba Alzoubi; Simone Minasi; Francesca Gianno; Manila Antonelli; Francesca Belardinilli; Felice Giangaspero; Marie-Lise Jaffrain-Rea; Francesca Romana Buttarelli
Journal:  Endocr Pathol       Date:  2022-01-06       Impact factor: 3.943

5.  Global changes in chromatin accessibility and transcription in growth hormone-secreting pituitary adenoma.

Authors:  Meng Wang; Chenxing Ji; Yichao Zhang; Zhiqiang Zhang; Yu Zhang; Huiping Guo; Nidan Qiao; Xiang Zhou; Xiaoyun Cao; Zhen Ye; Yifei Yu; Vladimir Melnikov; Wei Gong; Min He; Zhaoyun Zhang; Yao Zhao; Xuelong Wang; Gang Wei; Zhao Ye
Journal:  Endocrine       Date:  2022-08-10       Impact factor: 3.925

6.  Interaction of AIP with protein kinase A (cAMP-dependent protein kinase).

Authors:  Marie Helene Schernthaner-Reiter; Giampaolo Trivellin; Constantine A Stratakis
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

7.  DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas.

Authors:  Anat Ben-Shlomo; Nan Deng; Evelyn Ding; Masaaki Yamamoto; Adam Mamelak; Vera Chesnokova; Artak Labadzhyan; Shlomo Melmed
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

8.  Potential markers of disease behavior in acromegaly and gigantism.

Authors:  Laura C Hernández-Ramírez
Journal:  Expert Rev Endocrinol Metab       Date:  2020-05-06

9.  MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma.

Authors:  Scott Haston; Sara Pozzi; Gabriela Carreno; Saba Manshaei; Leonidas Panousopoulos; Jose Mario Gonzalez-Meljem; John R Apps; Alex Virasami; Selvam Thavaraj; Alice Gutteridge; Tim Forshew; Richard Marais; Sebastian Brandner; Thomas S Jacques; Cynthia L Andoniadou; Juan Pedro Martinez-Barbera
Journal:  Development       Date:  2017-05-15       Impact factor: 6.868

10.  Integrated multi-omics profiling of nonfunctioning pituitary adenomas.

Authors:  Zhenqing Wei; Cuiqi Zhou; Minghui Li; Ruocheng Huang; Hongjuan Deng; Stephen Shen; Renzhi Wang
Journal:  Pituitary       Date:  2020-11-18       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.